TAHO Pharmaceuticals Ltd

TAHO Pharmaceuticals Ltd

TTPEX:6467
199.00
TWD
-20.00
(-9.13%)
-1.83EPS
5.76BMarket Cap
Dec 02Next Earn

Total Valuation

TWD

As of June 30, 2026, TAHO Pharmaceuticals Ltd carries a market capitalization of 5.76B, placing it among publicly traded companies globally. Its enterprise value stands at 5.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.76B
Enterprise Value5.47B

Important Dates

TAHO Pharmaceuticals Ltd's next confirmed earnings release is scheduled for December 2, 2026.

Earnings Date12/2/2026

Share Statistics

As of June 30, 2026, TAHO Pharmaceuticals Ltd has 52.41M shares outstanding.

Shares Outstanding52.41M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 4,267.33, and the price-to-book ratio stands at 16.72.

PS Ratio4,267.33
PB Ratio16.72
P/TBV Ratio16.75
P/FCF Ratio-64.77
P/OCF Ratio-66.87

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 4,054.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.47B versus a market cap of 5.76B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4,054.58

Financial Position

As of June 30, 2026, TAHO Pharmaceuticals Ltd maintains a current ratio of 18.30, meaning it holds 18.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.48, indicating elevated leverage, while an interest coverage ratio of -501.82 demonstrates limited ability to service its debt obligations.

Current Ratio18.30
Quick Ratio18.07
Debt / Equity2.48
Debt / EBITDA-0.09
Interest Coverage-501.82

Financial Efficiency

TWD

Over the twelve months ended June 30, 2026, TAHO Pharmaceuticals Ltd posted a negative return on equity (ROE) of -24.94, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.38, reflecting losses generated across the asset base. The company generates approximately 51,923.08 in revenue per employee across its workforce of 26.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-24.94
Return on Assets (ROA)-23.38
Revenue Per Employee51,923.08
Employee Count26.00

Stock Price Statistics

TWD

As of the close on October 19, 2026, TAHO Pharmaceuticals Ltd's stock has gained approximately 20.37% over the past 52 weeks. The 50-day moving average sits at 194.20, while the 200-day moving average is 141.46.

52-Week Price Change20.37%
50-Day Moving Average194.20
200-Day Moving Average141.46

Income Statement

TWD

Over the twelve months ended June 30, 2026, TAHO Pharmaceuticals Ltd generated 1.35M in revenue and converted that into -95.84M in net income, yielding earnings per share of -1.83. EBITDA reached -93.34M, while operating income came in at -97.90M.

Revenue1.35M
Gross Profit1.22M
Operating Income-97.90M
Pretax Income-95.84M
Net Income-95.84M
EBITDA-93.34M
EBIT-97.90M
Earnings Per Share (EPS)-1.83

Balance Sheet

TWD

As of June 30, 2026, TAHO Pharmaceuticals Ltd holds 299.77M in cash and equivalents against 8.57M in total debt, resulting in a net debt position of -99.77M. Total book value stands at 344.86M, with working capital of 287.06M providing operational flexibility.

Cash & Cash Equivalents299.77M
Total Debt8.57M
Net Debt-99.77M
Equity (Book Value)344.86M
Book Value Per Share6.58
Working Capital287.06M

Cash Flow

TWD

TAHO Pharmaceuticals Ltd produced -86.16M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.79M in capital expenditures, free cash flow totaled -88.94M - equivalent to -1.70 per share.

Operating Cash Flow-86.16M
Capital Expenditures-2.79M
Free Cash Flow-88.94M
FCF Per Share-1.70

Margins

Over the twelve months ended June 30, 2026, TAHO Pharmaceuticals Ltd posted a gross margin of 90.44, reflecting its pricing power and cost economics. The operating margin of -7,251.93 and net profit margin of -7,099.33 provide insight into operational efficiency.

Gross Margin90.44
Operating Margin-7,251.93
Pretax Margin-7,099.33
Profit Margin-7,099.33
EBITDA Margin-6,914.00

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.54: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.02, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to TAHO Pharmaceuticals Ltd shareholders.

Shareholder Yield0.02
FCF Yield-1.54

Stock Splits

TAHO Pharmaceuticals Ltd's most recent stock split took place on October 21, 2025.

Last Split Date10/21/2025

Scores

As of June 30, 2026, TAHO Pharmaceuticals Ltd has an Altman Z-Score of 175.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score175.95